MX9304365A - Una forma de dosis osmotica para administrar tandospirona. - Google Patents

Una forma de dosis osmotica para administrar tandospirona.

Info

Publication number
MX9304365A
MX9304365A MX9304365A MX9304365A MX9304365A MX 9304365 A MX9304365 A MX 9304365A MX 9304365 A MX9304365 A MX 9304365A MX 9304365 A MX9304365 A MX 9304365A MX 9304365 A MX9304365 A MX 9304365A
Authority
MX
Mexico
Prior art keywords
administering
dosage form
tandospirone
osmotic dosage
patient
Prior art date
Application number
MX9304365A
Other languages
English (en)
Inventor
Atul D Ayer
Dana Ridzon
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of MX9304365A publication Critical patent/MX9304365A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se provee una forma de dosis para administrar un fármaco de la fórmula (I), a un paciente para producir un beneficio anciolítico en el paciente. Esta invención se refiere a una forma de dosis novedosa y útil que comprende el fármaco terapéutico representado por la fórmula general. La invención se refiere también a un método para tratar trastornos depresivos administrando la forma de dosis para suministrar el fármaco de la fórmula general a un paciente que requiere de terapia antidepresiva. La invención se refiere también a composiciones novedosas que comprenden la fórmula general, dichas composiciones son útiles para fabricar la forma de dosis.
MX9304365A 1993-01-27 1993-07-19 Una forma de dosis osmotica para administrar tandospirona. MX9304365A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/010,086 US5330762A (en) 1992-02-27 1993-01-27 Tandospiaine antidepressive therapy

Publications (1)

Publication Number Publication Date
MX9304365A true MX9304365A (es) 1994-07-29

Family

ID=21743762

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304365A MX9304365A (es) 1993-01-27 1993-07-19 Una forma de dosis osmotica para administrar tandospirona.

Country Status (16)

Country Link
US (1) US5330762A (es)
EP (1) EP0681473B1 (es)
JP (1) JPH08505869A (es)
KR (1) KR100293305B1 (es)
AT (1) ATE173926T1 (es)
AU (1) AU674898B2 (es)
CA (1) CA2152673A1 (es)
DE (1) DE69322411T2 (es)
DK (1) DK0681473T3 (es)
ES (1) ES2125354T3 (es)
FI (1) FI953566A0 (es)
MX (1) MX9304365A (es)
NO (1) NO952900L (es)
NZ (1) NZ257244A (es)
WO (1) WO1994016699A1 (es)
ZA (1) ZA937746B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9609094D0 (en) * 1996-05-01 1996-07-03 Univ Strathclyde Delivery device
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
DE69930952T2 (de) * 1998-11-02 2006-08-31 Alza Corp., Mountain View Verfahren und Vorrichtung zur kontrollierten Abgabe pharmazeutischer Mittel sowie Dosierungsform hierfür
EP1428535A1 (en) * 1998-11-02 2004-06-16 ALZA Corporation Controlled delivery of antidepressants
JP2005527578A (ja) * 2002-04-08 2005-09-15 ランバクシー ラボラトリーズ リミテッド 有用な尿選択的α１Ａアドレナリン受容体遮断薬としてのα，ω−ジカルボキシイミド誘導体
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7892472B2 (en) 2004-08-12 2011-02-22 United States Gypsum Company Method of making water-resistant gypsum-based article
US20060247249A1 (en) * 2005-11-16 2006-11-02 Mohammad Salman Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers
EP2429514A1 (en) * 2009-05-13 2012-03-21 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof
US20130303497A1 (en) 2010-08-05 2013-11-14 Conrig Pharma Aps Deuterated 5-ht1a receptor agonists
CN113018271B (zh) * 2019-12-25 2022-08-09 四川科瑞德制药股份有限公司 一种坦度螺酮药物组合物及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4507303A (en) * 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
JPS58126865A (ja) * 1981-12-22 1983-07-28 Sumitomo Chem Co Ltd 環状イミド誘導体及びその酸付加塩
JPS5976059A (ja) * 1982-10-21 1984-04-28 Sumitomo Chem Co Ltd 環状イミド誘導体及びその酸付加塩
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5011841B1 (en) * 1989-11-14 1994-09-06 Pfizer Treatment of depression
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same

Also Published As

Publication number Publication date
JPH08505869A (ja) 1996-06-25
FI953566A (fi) 1995-07-26
ATE173926T1 (de) 1998-12-15
EP0681473A1 (en) 1995-11-15
US5330762A (en) 1994-07-19
WO1994016699A1 (en) 1994-08-04
KR100293305B1 (ko) 2001-09-17
FI953566A0 (fi) 1995-07-26
ZA937746B (en) 1994-08-10
CA2152673A1 (en) 1994-08-04
NZ257244A (en) 1996-10-28
DE69322411D1 (de) 1999-01-14
KR960700058A (ko) 1996-01-19
EP0681473B1 (en) 1998-12-02
ES2125354T3 (es) 1999-03-01
NO952900D0 (no) 1995-07-21
AU5354594A (en) 1994-08-15
AU674898B2 (en) 1997-01-16
NO952900L (no) 1995-09-26
DE69322411T2 (de) 1999-04-29
DK0681473T3 (da) 1999-08-16

Similar Documents

Publication Publication Date Title
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
ES2545205T3 (es) Combinación de azelastina y ciclesonida
ES2152485T3 (es) Procedimiento para preparar comprimidos que contienen amoxicilina y clavulanato recubiertos de una pelicula polimerica acuosa.
ES2194210T3 (es) Forma de dosificacion para suministrar una dosis ascendente de farmaco.
CY1111061T1 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
IT1270594B (it) Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DK0738270T3 (da) Dihydropyrazolopyrroler
MX9304365A (es) Una forma de dosis osmotica para administrar tandospirona.
AR029471A1 (es) Forma cristalina de la sal de disodio del acido n- [4- [2-(2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil]benzoil] -l-glutrmico-forma cristalina heptahidrato-; procedimiento de uso de dicha forma en la fabricacion de medicamentos para el tratamiento del cancer; formulaciones farmaceu
DE60143911D1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
KR960700054A (ko) 파킨슨씨 병 및 파킨슨 증후군의 치료에 리루졸의 이용(application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes)
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
BR0012901A (pt) Medicamentos de ß - carbolina
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
ZA874812B (en) Drug
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
AR042153A1 (es) Uso de los compuestos 2,5- dihidroxibencenosulfonicos para la fabricacion de un medicamento
BR0213434A (pt) Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável
MX9306998A (es) Una composicion terapeutica de tandospirona y forma de dosis paraadministrarla.
ES2138226T3 (es) Derivados del acido imidazo(1,2-a)indeno(1,2-e)pirazina-2-carboxilico, su preparacion y los medicamentos que les contienen.
AR042152A1 (es) Uso de los compuestos 2,5 dihidroxibencesulfonicos para la fabricacion de un medicamento para pacientes diabeticos
HUP9802005A2 (hu) Nátrium/hidrogén-csere inhibitorok alkalmazása különböző anyagok által a szívre gyakorolt nem kívánt hatások csökkentésére alkalmas gyógyszerkészítmények előállítására